These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 31749076

  • 1. Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach.
    Solms A, Iorio A, Ahsman MJ, Vis P, Shah A, Berntorp E, Garmann D.
    Clin Pharmacokinet; 2020 May; 59(5):605-616. PubMed ID: 31749076
    [Abstract] [Full Text] [Related]

  • 2. BAY 94-9027, a PEGylated recombinant factor VIII, exhibits a prolonged half-life and higher area under the curve in patients with severe haemophilia A: Comprehensive pharmacokinetic assessment from clinical studies.
    Shah A, Coyle T, Lalezari S, Fischer K, Kohlstaedde B, Delesen H, Radke S, Michaels LA.
    Haemophilia; 2018 Sep; 24(5):733-740. PubMed ID: 29963724
    [Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
    Zhang Y, Roberts J, Tortorici M, Veldman A, St Ledger K, Feussner A, Sidhu J.
    J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
    Rode F, Almholt K, Petersen M, Kreilgaard M, Kjalke M, Karpf DM, Groth AV, Johansen PB, Larsen LF, Loftager M, Haaning J.
    J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
    [Abstract] [Full Text] [Related]

  • 9. Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis--new insight provided by pharmacokinetic modelling.
    Gringeri A, Wolfsegger M, Steinitz KN, Reininger AJ.
    Haemophilia; 2015 May; 21(3):300-306. PubMed ID: 25643824
    [Abstract] [Full Text] [Related]

  • 10. Improved Pharmacokinetics with BAY 81-8973 Versus Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method: A Randomized Pharmacokinetic Study in Patients with Severe Hemophilia A.
    Shah A, Solms A, Garmann D, Katterle Y, Avramova V, Simeonov S, Lissitchkov T.
    Clin Pharmacokinet; 2017 Sep; 56(9):1045-1055. PubMed ID: 28005225
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.
    Chen ZP, Li PJ, Li G, Tang L, Zhen YZ, Wu XY, Cheng XL, Luke KH, Blanchette VS, Poon MC, Ding QL, Wu RH.
    Chin Med J (Engl); 2018 Aug 05; 131(15):1780-1785. PubMed ID: 29848837
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
    Reding MT, Ng HJ, Poulsen LH, Eyster ME, Pabinger I, Shin HJ, Walsch R, Lederman M, Wang M, Hardtke M, Michaels LA.
    J Thromb Haemost; 2017 Mar 05; 15(3):411-419. PubMed ID: 27992112
    [Abstract] [Full Text] [Related]

  • 13. Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned - importance of including samples with factor VIII levels below the quantitation limit.
    Garmann D, McLeay S, Shah A, Vis P, Maas Enriquez M, Ploeger BA.
    Haemophilia; 2017 Jul 05; 23(4):528-537. PubMed ID: 28220555
    [Abstract] [Full Text] [Related]

  • 14. Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans.
    Kim MS, Hajducek DM, Gilbert JC, Iorio A, Jilma B, Edginton AN.
    AAPS J; 2024 Jul 12; 26(4):81. PubMed ID: 38992298
    [Abstract] [Full Text] [Related]

  • 15. Clinical benefits of a Bayesian model for plasma-derived factor VIII/VWF after one year of pharmacokinetic-guided prophylaxis in severe/moderate hemophilia A patients.
    Megías-Vericat JE, Bonanad S, Haya S, Cid AR, Marqués MR, Ferrada A, Monte-Boquet E, Pérez-Alenda S, Bosch P, Querol-Giner F, Poveda JL.
    Thromb Res; 2021 Sep 12; 205():99-105. PubMed ID: 34293540
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
    Solms A, Shah A, Berntorp E, Tiede A, Iorio A, Linardi C, Ahsman M, Mancuso ME, Zhivkov T, Lissitchkov T.
    Ann Hematol; 2020 Nov 12; 99(11):2689-2698. PubMed ID: 32974838
    [Abstract] [Full Text] [Related]

  • 18. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens.
    Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P, Fritsch S, Casey K, Spotts G, Ewenstein BM.
    J Thromb Haemost; 2010 Feb 12; 8(2):269-75. PubMed ID: 19943875
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetic drug evaluation of recombinant factor VIII for the treatment of hemophilia A.
    Castaman G, Linari S.
    Expert Opin Drug Metab Toxicol; 2018 Feb 12; 14(2):143-151. PubMed ID: 29257899
    [Abstract] [Full Text] [Related]

  • 20. Safety and pharmacokinetics of a recombinant factor VIII with pegylated liposomes in severe hemophilia A.
    Powell JS, Nugent DJ, Harrison JA, Soni A, Luk A, Stass H, Gorina E.
    J Thromb Haemost; 2008 Feb 12; 6(2):277-83. PubMed ID: 18039351
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.